Contraceptive Devices Market Report 2024

The contraceptive devices market size has grown strongly in recent years. It will grow from $12.05 billion in 2023 to $12.8 billion in 2024 at a compound annual growth rate (CAGR) of 6.3%. The growth during the historic period can be attributed to increasing awareness about the importance of family planning and contraceptive methods, government initiatives, a rising global population, a greater focus on women's health and empowerment, and improved access to healthcare facilities.

The contraceptive devices market size is expected to see strong growth in the next few years. It will grow to $16.43 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to rising awareness of sexual health and STD prevention, the economic benefits of controlling family size, growing cultural acceptance of contraceptive use, a high proportion of young people in the reproductive age group, and the influence of social media in spreading awareness. Major trends expected during this period include innovations in contraceptive technologies, educational campaigns by NGOs and health organizations, advancements in pharmaceutical formulations, the availability of a wide range of contraceptive products, and increased investment in research and development for new contraceptive methods.

The increasing prevalence of sexually transmitted diseases (STDs) is expected to drive growth in the contraceptive device market. STDs are infections primarily spread through sexual contact, affecting various body parts and potentially causing a range of symptoms and health issues. Rising STD rates are linked to factors such as higher sexual activity, inadequate protection, insufficient sexual health education, and difficulties accessing healthcare and testing. Contraceptive devices, particularly condoms, are essential for preventing STDs as they create a barrier that reduces the risk of transmission by preventing direct contact with infectious fluids and lesions. For example, a report by the UK Health Security Agency in July 2024 noted 401,800 new STI diagnoses in England in 2023, a 4.7% increase from the previous year's 383,789 cases. Gonorrhoea diagnoses rose by 7.5%, from 79,268 in 2022 to 85,223 in 2023, while infectious syphilis diagnoses increased by 9.4%, from 8,693 in 2022 to 9,513 in 2023. This growing prevalence of STDs is driving demand for contraceptive devices.

Companies in the contraceptive device market are focusing on developing innovative products, such as contraceptive vaginal rings, to offer convenient, low-maintenance birth control with a once-a-month insertion. A contraceptive vaginal ring is a flexible, hormone-releasing device placed in the vagina, which prevents pregnancy by continuously releasing hormones to inhibit ovulation and thicken cervical mucus. For instance, in October 2023, Xiromed LLC, a US-based pharmaceutical company, introduced the EnilloRing. This contraceptive vaginal ring, developed by Xiromed, combines etonogestrel and ethinyl estradiol and is designed for long-term use, remaining in place for three weeks, followed by a one-week ring-free interval.

In December 2023, Aditxt, a US-based life sciences company, acquired Evofem Biosciences for $100 million. This acquisition includes Evofem’s FDA-approved hormone-free contraceptive gel, Phexxi® (lactic acid, citric acid, and potassium bitartrate). Aditxt aims to use this acquisition to bolster its focus on innovations in autoimmunity, health metrics, life-extending transplant technologies, population health, and women's health. This acquisition enhances Aditxt's collaborative ecosystem and maximizes the potential of its subsidiaries. Evofem Biosciences is a US-based manufacturer of contraceptive devices.

Major companies operating in the contraceptive devices market are Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Boehringer Ingelheim International GmbH., Teva Pharmaceutical Industries Ltd., Mylan N.V., Organon Group, Hologic Inc., CooperSurgical Inc., Cipla Inc., Mankind Pharma Ltd., TTK HealthCare Ltd., Zondervan, Merck Sharp & Dohme Corp., Evofem Biosciences Inc., Veru Inc., Medisafe Inc., Agile Therapeutics Inc., Janssen Global Services LLC, HLL Lifecare Ltd., Mayer Laboratories Inc., V-Care Pharma Pvt. Ltd., Vardhaman Lifecare Pvt. Ltd., Actavis Pharma LLC, Pregna International Limited.

North America was the largest region in the contraceptive devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the contraceptive devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the contraceptive devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Contraceptive devices are medical tools designed to prevent pregnancy. They come in various forms, each with distinct mechanisms and levels of effectiveness. These devices are primarily used to avoid unintended pregnancies and, in some cases, offer protection against sexually transmitted infections (STIs).

The main types of contraceptive devices include male contraceptive devices, female contraceptive devices, female condoms, diaphragms and sponges, vaginal rings, intrauterine devices, sub-dermal implants, and others. Male contraceptive devices, such as condoms and vasectomy procedures, are methods used by men to prevent pregnancy. They include both hormonal and barrier methods. These devices are distributed through various channels, including hospital pharmacies, retail pharmacies, clinics, online platforms, public channels, non-governmental organizations (NGOs), and others.

The contraceptive devices market research report is one of a series of new reports that provides contraceptive devices market statistics, including contraceptive devices industry global market size, regional shares, competitors with a contraceptive devices market share, detailed contraceptive devices market segments, market trends and opportunities, and any further data you may need to thrive in the contraceptive devices industry. This contraceptive devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The contraceptive devices market consists of sales of cervical caps, hormonal injections, emergency contraceptive devices and sterilization products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.